190 related articles for article (PubMed ID: 24906252)
1. Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects.
Ahn LY; Kim SE; Yi S; Dingemanse J; Lim KS; Jang IJ; Yu KS
Am J Cardiovasc Drugs; 2014 Oct; 14(5):377-85. PubMed ID: 24906252
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
Sidharta PN; van Giersbergen PL; Dingemanse J
J Clin Pharmacol; 2013 Nov; 53(11):1131-8. PubMed ID: 23900878
[TBL] [Abstract][Full Text] [Related]
3. Macitentan: entry-into-humans study with a new endothelin receptor antagonist.
Sidharta PN; van Giersbergen PL; Halabi A; Dingemanse J
Eur J Clin Pharmacol; 2011 Oct; 67(10):977-84. PubMed ID: 21541781
[TBL] [Abstract][Full Text] [Related]
4. Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.
Sidharta PN; van Giersbergen PL; Wolzt M; Dingemanse J
Br J Clin Pharmacol; 2014 Nov; 78(5):1035-42. PubMed ID: 24962473
[TBL] [Abstract][Full Text] [Related]
5. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.
Sidharta PN; Melchior M; Kankam MK; Dingemanse J
Drug Des Devel Ther; 2019; 13():949-964. PubMed ID: 30962677
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan.
Sidharta PN; Treiber A; Dingemanse J
Clin Pharmacokinet; 2015 May; 54(5):457-71. PubMed ID: 25860376
[TBL] [Abstract][Full Text] [Related]
7. Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension.
Krause A; Zisowsky J; Dingemanse J
Pulm Pharmacol Ther; 2018 Apr; 49():140-146. PubMed ID: 29501590
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Sidharta PN; Krähenbühl S; Dingemanse J
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
[TBL] [Abstract][Full Text] [Related]
9. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.
Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ
Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642
[TBL] [Abstract][Full Text] [Related]
10. Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects.
Lindegger N; Sidharta PN; Reseski K; Dingemanse J
Pulm Pharmacol Ther; 2014 Oct; 29(1):41-8. PubMed ID: 24813561
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.
Atsmon J; Dingemanse J; Shaikevich D; Volokhov I; Sidharta PN
Clin Pharmacokinet; 2013 Aug; 52(8):685-92. PubMed ID: 23568224
[TBL] [Abstract][Full Text] [Related]
12. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.
Bruderer S; Aänismaa P; Homery MC; Häusler S; Landskroner K; Sidharta PN; Treiber A; Dingemanse J
AAPS J; 2012 Mar; 14(1):68-78. PubMed ID: 22189899
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Macitentan in Patients With Pulmonary Arterial Hypertension and Comparison With Healthy Subjects.
Issac M; Dingemanse J; Sidharta PN
J Clin Pharmacol; 2017 Aug; 57(8):997-1004. PubMed ID: 28378883
[TBL] [Abstract][Full Text] [Related]
14. Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects.
Fontes MSC; Dingemanse J; Sidharta PN
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):718-725. PubMed ID: 33063477
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects.
Sidharta PN; Dietrich H; Dingemanse J
Clin Drug Investig; 2014 Aug; 34(8):545-52. PubMed ID: 24861134
[TBL] [Abstract][Full Text] [Related]
16. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension].
Avdeev SN
Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621
[TBL] [Abstract][Full Text] [Related]
17. Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.
Angus JA; Soeding PF; Hughes RJA; Wright CE
Eur J Pharmacol; 2017 Jun; 804():111-116. PubMed ID: 28300593
[TBL] [Abstract][Full Text] [Related]
18. Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model.
Hoenicka M; Golovchenko S; Englert L; Spaeth M; Shoshiashvili L; Großer C; Hofmann HS; Ried M
Cardiovasc Drugs Ther; 2019 Jun; 33(3):287-295. PubMed ID: 30826900
[TBL] [Abstract][Full Text] [Related]
19. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
Bolli MH; Boss C; Binkert C; Buchmann S; Bur D; Hess P; Iglarz M; Meyer S; Rein J; Rey M; Treiber A; Clozel M; Fischli W; Weller T
J Med Chem; 2012 Sep; 55(17):7849-61. PubMed ID: 22862294
[TBL] [Abstract][Full Text] [Related]
20. Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension.
Clozel M
Am J Physiol Regul Integr Comp Physiol; 2016 Oct; 311(4):R721-R726. PubMed ID: 27534881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
